Assessing glucocorticoid toxicity: are the measures sensitive enough?
- PMID: 38251606
- DOI: 10.1016/S2665-9913(23)00037-1
Assessing glucocorticoid toxicity: are the measures sensitive enough?
Conflict of interest statement
We are all inventors of a treatment-focused patient reported outcome to measure the effect of glucocorticoids in patients with rheumatic diseases (the Steroid PRO) and have received a Steroid PRO research grant from Vifor Pharma; GCA PRO (a disease specific patient reported outcome to measure the impact of giant cell arteritis and its treatment) funding from the National Institute for Health and Care Research, Research for Patient Benefit Grant; and a Steroid PRO cross-condition validation study research grant from Sanofi.
Comment on
-
Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.Lancet Rheumatol. 2023 Mar;5(3):e130-e138. doi: 10.1016/S2665-9913(23)00030-9. Epub 2023 Feb 20. Lancet Rheumatol. 2023. PMID: 38251609 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
